Sanovel İlaç Information

Founded in 1983 by Pharmacist Erol Toksöz, Sanovel stands as one of the leading pharmaceutical companies in Türkiye. Boasting an annual production capacity of 227 million units and EU GMP (Good Manufacturing Practices) certification, the company aspires to be a global pharmaceutical company. This vision is driven by robust R&D, an extensive product portfolio featuring over 60 brands and 180 products, and a dedicated team of over 1,600 individuals committed to fostering long and healthy lives. Distinguished as the first and only Turkish pharmaceutical company to be approved by the American Food and Drug Administration (FDA), acknowledged as the world's foremost health authority, Sanovel obtained approval without encountering any major or critical observations. With exceptional capabilities in terms of R&D, patents and intellectual property rights, Sanovel is the pioneering company to offer equivalent products to the market in a wide range of treatment areas. Sanovel R&D Center & Production Campus in İstanbul Silivri, started production in 2006. The production site comprises the main production unit, cephalosporin production unit, refining unit, elevated storage and social recreational facility. The production capacity is 227 million units per year. Enjoying a leadership position in intellectual property competence within the industry, Sanovel has consistently maintained its status as the patent champion of the Turkish pharmaceutical industry, a title attributable to the company's exceptional work in the realm of intellectual property. Guided by a strong vision, Sanovel centers its entire operation around sustainability, aiming for a balanced and valuable life for its hundreds of highly competent and passionate employees. Sanovel is dedicated to contributing to the Turkish pharmaceutical industry and the national economy, a commitment it has upheld for four decades, with the overarching goal of promoting a lifelong health worldwide.